# A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

> **NCT05597020** · PHASE4 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Insomnia Disorder
- Nocturia

## Interventions

- **DRUG:** Daridorexant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05597020
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-16
- **Primary completion:** 2024-04-12
- **Final completion:** 2024-04-18
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05597020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05597020, "A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05597020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*